Immunohistochemical profiling helps differentiate synchronous primary breast invasive carcinoma from metastatic ovarian carcinoma
One woman diagnosed with two different types of cancer simultaneously
This case report and literature review describes a patient with concurrent primary breast cancer and metastatic high-grade serous ovarian ca…
A rare case reveals how one patient can have both breast and ovarian cancer at once, highlighting a complex diagnostic challenge.
Angiogenesis inhibitors combined with chemotherapy improve progression-free survival in advanced breast cancer patients
Adding angiogenesis inhibitors to chemotherapy helps advanced breast cancer patients stay disease-free longer
This systematic review and meta-analysis of phase II and III trials evaluated angiogenesis inhibitors combined with chemotherapy versus chem…
A large review of eight thousand four hundred patients found that adding angiogenesis inhibitors to standard chemotherapy improved how long …
Lenvatinib plus PD-1 inhibitor improves survival versus bevacizumab plus PD-1 inhibitor in unresectable hepatocellular carcinoma
Meta-analysis shows lenvatinib-based regimens improve survival for unresectable liver cancer in East Asia
This systematic review and meta-analysis evaluated first-line treatment for unresectable hepatocellular carcinoma in East Asian populations.
A meta-analysis of East Asian patients with unresectable liver cancer found lenvatinib-based regimens improved survival compared to bevacizu…
Network meta-analysis finds similar overall survival for three HCC regimens
Three drugs show similar survival for unresectable liver cancer patients
A network meta-analysis of 11 studies in unresectable hepatocellular carcinoma found no statistically significant differences in overall sur…
Three drugs show similar survival for unresectable liver cancer patients, offering patients clearer choices without proving one option is de…
Case report of YL205 antibody-drug conjugate in platinum-resistant ovarian carcinoma
First patient achieves complete response with new ovarian cancer drug YL205
This is a single-patient case report of a 40-year-old woman with platinum-resistant, BRCA-wildtype high-grade serous ovarian carcinoma treat…
A single patient with advanced ovarian cancer achieved a complete response after 24 weeks of treatment with YL205, a new antibody-drug conju…
Meta-analysis shows bevacizumab plus FOLFOX improves response rates without increasing common toxicities in advanced colorectal cancer
Adding bevacizumab to standard chemo improves tumor response in advanced colorectal cancer
This systematic review and meta-analysis evaluated bevacizumab combined with FOLFOX versus FOLFOX alone in patients with advanced or metasta…
A large review found that adding bevacizumab to standard chemotherapy improves how well tumors respond and keeps disease under control longe…
Angiogenic ccRCC tumors show higher pancreatic metastasis rate in phase II trial
Pancreatic Metastases Predict Better Sunitinib Response in Kidney Cancer
This phase II RCT of 305 treatment-naive ccRCC patients found that angiogenic tumors had a higher rate of pancreatic metastases (21% vs. 6.9…
Kidney tumors with certain genetic patterns are more likely to spread to the pancreas. Patients with these pancreatic metastases respond bet…
Bayesian network meta-analysis of first-line immunotherapy versus TKI for advanced hepatocellular carcinoma
Immunotherapy Outperforms Standard Care for Advanced Liver Cancer
This Bayesian network meta-analysis of 7,301 patients with advanced hepatocellular carcinoma synthesized evidence from randomized trials. It…
A new analysis of 10 clinical trials shows that immunotherapy drugs help people with advanced liver cancer live longer than standard treatme…
Meta-analysis shows improved survival with PD-1/PD-L1 inhibitor plus bevacizumab versus sorafenib in advanced HCC
New Drug Combo Outperforms Standard Care for Liver Cancer
This meta-analysis evaluated PD-1/PD-L1 inhibitor plus bevacizumab versus sorafenib in treatment-naive individuals with advanced hepatocellu…
A powerful two-drug combination cuts the risk of death by 35 percent compared to the standard treatment for people with advanced liver cance…
Meta-analysis of bevacizumab therapy in recurrent glioblastoma multiforme shows associations with improved outcomes
Bevacizumab therapy linked to better survival and fewer bleeding risks in recurrent brain cancer
This meta-analysis evaluates bevacizumab (BEV) therapy, temozolomide (TMZ), and lomustine in patients with recurrent glioblastoma multiforme…
A large review of patients with recurrent brain cancer found bevacizumab therapy linked to better survival and fewer bleeding risks compared…
Review of ovarian cancer treatments including olaparib, bevacizumab, and durvalumab discusses limitations and biomarkers
New drug combos target hidden cancer switches to stop resistance
This narrative review examines ovarian cancer management involving olaparib, bevacizumab, and durvalumab.
Hidden chemical changes in ovarian cancer cells help them hide from drugs, but new combinations might finally stop them from adapting and gr…
Neoadjuvant mFOLFOXIRI plus bevacizumab reduces peritoneal tumor burden in colorectal cancer patients
Chemo before surgery may reduce tumor burden in colorectal cancer patients
This phase II randomized controlled trial evaluated 53 patients with resectable peritoneal metastasis of colorectal cancer.
A trial suggests chemo before surgery might lower tumor markers for colorectal cancer patients with spread to the abdomen.